anmelden
Novartis Aktie
128,20
EUR
+1,04
EUR
+0,82
%
119,10
CHF
+1,38
CHF
+1,17
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 235,48 Mrd. EUR
KGV 18,30Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Goldman Sachs Group Inc. | 113,00 CHF | - | 01.10.2026 | |
| Deutsche Bank AG | 120,00 CHF | - | 29.09.2026 | |
| UBS AG | - | - | 17.09.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 105,00 CHF | - | 11.09.2026 | |
| RBC Capital Markets | 120,00 CHF | - | 09.09.2026 | |
| Jefferies & Company Inc. | 110,00 CHF | - | 08.09.2026 | |
| Barclays Capital | 130,00 CHF | - | 08.09.2026 | |
| JP Morgan Chase & Co. | 135,00 CHF | - | 10.08.2026 | |
| DZ BANK | - | - | 22.07.2026 | |
| Bernstein Research | 132,84 CHF | - | 22.07.2026 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 9 | 1 | 0 | 157,78 GBP | - |
| Bayer | 7 | 2 | 0 | 56,56 EUR | - |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 1 | 2 | 0 | 5,70 EUR | +103,86% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 3 | 5 | 2 | 21,34 GBP | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 3 | 5 | 0 | 147,57 EUR | +6,97% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 1 | 8 | 1 | 120,73 CHF | - |
| Pfizer Inc. | 2 | 5 | 1 | 27,43 USD | - |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Roche Holding AG Inhaber-Partizipationsschein | 2 | 2 | 0 | - | - |
| Sanofi S.A. | 5 | 5 | 0 | 93,53 EUR | - |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |
